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Background: Small interfering RNA (siRNA) can silence target genes in the cytoplasm and 
be a major tool in gene therapy. Vascular endothelial growth factor (VEGF), a potent regulator 
of angiogenesis, is overexpressed in most tumors and is closely associated with tumor growth 
and metastasis. It has been shown that inhibition of VEGF expression by siRNA is an effective 
and useful method for antiangiogenic tumor therapy.
Methods: In the present study, we synthesized a targeted delivery system of PEI-PEG-APRPG 
incorporating angiogenic vessel-homing Ala-Pro-Arg-Pro-Gly (APRPG) peptide into cationic 
polyethylenimine (PEI) via a hydrophilic poly(ethylene glycol) (PEG) spacer.
Results: PEI-PEG-APRPG effectively condensed siRNA into 20–50 nm nanoparticles with 
a positive surface charge using a suitable N/P ratio. The siRNA/PEI-PEG-APRPG complex 
effectively enhanced the stability of siRNA in RNase A, and improved the proliferation-inhibiting 
ability and transfection efficiency of siRNA in vitro and tumor accumulation in vivo. In addition, 
the siRNA/PEI-PEG-APRPG complex exhibited high efficiency as antitumor therapy with regard 
to tumor growth, microvessel density, and VEGF protein and mRNA levels.
Conclusion: These findings suggest that PEI-PEG-APRPG effectively delivers siRNA to tumors 
overexpressing VEGF and thereby inhibits tumor growth.
Keywords: PEI-PEG-APRPG, VEGF siRNA, gene delivery, tumor-targeted, antiangiogenic 
therapy
Introduction
Since RNA interference was discovered in Caenorhabditis elegans a decade ago, 
many researchers worldwide have used this technique to downregulate disease-causing 
genes in various human diseases, including viral infections, ocular diseases, neuro-
degenerative disorders, and cancers.1,2 RNA interference, a process characterized by 
sequence-specific, post-transcriptional gene silencing directed by short interfering 
21–23 nucleotide double-stranded RNA (siRNA) can specifically and markedly reduce 
the expression of targeted mRNA.3 In siRNA therapeutics, a lot of vectors for siRNA 
delivery have been reported to achieve perfect results with in vitro applications, but 
these vectors were mostly inappropriate for use in vivo or are only administered 
locally.4 To be administered systemically, targeted siRNA delivery should be designed 
to improve accumulation of siRNA at three levels, ie, the target tissue, target cell, 
and intracellular target site of action.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Angiogenesis (also known as neovascularization) is 
defined as the development of new blood vessels from pre-
existing vessels, and is an attractive target for cancer therapy 
because it is essential for tumor growth and hematogenous 
metastasis.5 Growth and survival of tumors depends on the 
tumor vessels being able to supply oxygen and nutrient 
substances. Tumors can only reach a size of 1–2 mm3 
without angiogenesis.6–8 Vascular endothelial growth factor 
(VEGF) is a positive and potent regulator of angiogenesis.9,10 
Inhibition of VEGF production by siRNA was reported to 
be an effective and useful method for antiangiogenic tumor 
therapy in vitro and in vivo.11 Additionally, Ala-Pro-Arg-
Pro-Gly (APRPG) peptide was identified as an angiogenic 
vessel-homing peptide by Oku et al.12 They isolated the 
APRPG peptide which specifically accumulated at the 
angiogenic site using a phage-displayed peptide library in 
an angiogenesis model in mice, suggesting that APRPG is 
a useful probe for angiogenic vessels, although the target 
molecule was still unknown. Specifically, APRPG only 
adhered to neovascular endothelial cells, and not to tumor 
cells or other normal cells. Doxorubicin, CNDAC (an 
antitumor nucleoside antimetabolite), and SU1498 (a receptor 
tyrosine kinase inhibitor of VEGF receptor 2) encapsulated in 
the APRPG-modified liposomes have achieved a remarkable 
therapeutic effect in some tumor models, such as colon 
26 NL-17 carcinoma and doxorubicin-resistant P388 solid 
tumor cell lines.13–15
siRNA delivery systems include viral and nonviral 
vectors. Nonviral vectors possess several advantages, 
including safety and easy modification, but they have lower 
transfection efficiency than viral vectors. Polyethylenimine 
(PEI) has a high cationic charge density and can 
bind and condense siRNA, protecting siRNA against 
nucleases and reducing renal clearance. siRNA-PEG/PEI 
polyelectrolyte complexes formulated using poly(ethylene 
glycol) (PEG) modified siRNA (PEG-siRNA), and PEI 
has been successfully applied.16 In our previous report, 
oligodeoxynucleotide (ODN) was mixed with PEI-PEG 
after PEG stealth or long-circulation modification on PEI 
(PEI-PEG), and the ODN/PEI-PEG polyelectrolyte complex 
had increased activity as a vector for delivery of genes into 
cells.17 This indicates that PEI-PEG could be useful for 
siRNA delivery.
In the present study, we prepared a targeted delivery 
system of siRNA/PEI-PEG-APRPG polyelectrolyte 
complexes and evaluated the efficacy of PEI-PEG-APRPG 
as an siRNA-delivering agent in vitro and in vivo.
Materials and methods
Materials
Branched PEI, average molecular weight 25 kDa, average 
polymerization degree 580, dextran fluorescein anionic 
(DFA, molecular weight 3000), RNase A, and diethypyro-
carbonate were purchased from Sigma-Aldrich (St Louis, 
MO). N-hydroxysuccinimide-vinyl sulfone polyethylene 
glycol (NHS-PEG-VS, molecular weight 7452) and 
N-hydroxysuccinimide-methyl poly(ethylene glycol) (PEG-
NHS, molecular weight 4834) were custom synthesized by 
Jenkem Technology Co Ltd (Beijing, China). APRPG peptide 
was custom synthesized by SciLight Biotechnology (Beijing, 
China). Fetal bovine serum was purchased from Wuhan Sanli 
Biotechnology Co Ltd (Wuhan, China). Dulbecco’s   Modified 
Eagle’s Medium was purchased from Tianrunshanda Biotech 
Co Ltd (Beijing, China). 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was purchased from 
Amresco Inc (Solon, OH). TRIzol® Reagent was obtained 
from Invitrogen (Carlsbad, CA). All the solutions and 
instruments referring to RNA were treated with 0.1% diet-
hypyrocarbonate. All other chemicals and reagents were of 
analytical grade.
A siRNA targeting human VEGF (sense: 5′-GGAG 
UACCCUGAUGAGAUCdTdT-3′; antisense: 5′-GAU 
CUCAUCAGGGUACUCCdTdT-3′) modified with an 
O-methyl group (2′-O-Me) used in vivo was custom 
  synthesized by GenePharma (Shanghai, China), and the 
same sequence siRNA and fluorescein isothiocyanate-labeled 
siRNA (FITC-siRNA) used in vitro were custom synthesized 
by GenePharma (Shanghai, China).
synthesis and characterization of PeI-Peg 
and PeI-Peg-APrPg derivatives
Two PEGylated forms of PEI were prepared, one with PEG 
having an APRPG peptide at its distal end (PEI-PEG-APRPG) 
and the other with PEG lacking the peptide (PEI-PEG).
Synthesis of PEI-PEG was carried out as follows. A six-
fold molar ratio of PEG-NHS was added to PEI in KH2PO4-
NaOH solution (50 mM KH2PO4, 39.5 mM NaOH, pH 7.4) 
and reacted by gentle stirring for 48 hours at room tempera-
ture. The final product, PEI-PEG, was purified by dialysis 
(dialysis tubing with a molecular weight cutoff 8000–12,000 
Da) against distilled water and lyophilized. The composition 
of PEI-PEG derivative was analyzed by thin-layer chroma-
tography, Fourier transform infrared spectra (KBr pellet), 
gel permeation chromatography, and 1H-nuclear magnetic 
resonance (NMR). 1H-NMR spectra were obtained on the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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JNM-AL300 FT NMR system from JEOL (Tokyo, Japan) 
with standard proton parameters. Chemical shifts were 
referenced to the solvent D2O resonance at approximately 
4.7 ppm.
A heterobifunctional PEG, ie, NHS-PEG-VS, was used 
as a linker between the PEI and APRPG peptide, and was 
carried out as follows in two steps. In the first reaction step, 
APRPG peptide was conjugated to NHS-PEG-VS at 2:1 
(mol/mol) in anhydrous dimethyl formamide containing a 
2.5-fold molar ratio of triethylamine and reacted by gentle 
stirring for six hours at room temperature under nitrogen. 
The intermediate APRPG-PEG-VS was precipitated out by 
cold anhydrous ether and dried. Conjugation was confirmed 
by matrix-assisted laser desorption/ionization time of flight 
mass spectral analysis (MALDI-TOF-MS) and thin-layer 
chromatographic analysis.
In the second step of synthesis, a 12-fold molar ratio of 
APRPG-PEG-VS intermediate was mixed with PEI solution 
in KH2PO4-NaOH solution (pH 9.4), and reacted by gentle 
stirring for 24 hours at room temperature. Completion of 
conjugation was confirmed by the disappearance of APRPG-
PEG-VS on thin-layer chromatography. The final product, 
PEI-PEG-APRPG, was purified by dialysis against distilled 
water (dialysis tubing with a molecular weight cutoff 
8000–12,000 Da) and lyophilized.
The substitute degree of conjugation of PEG or APRPG-
PEG to PEI was determined by 1H-NMR spectrometry, from 
the ratio of the area under the peaks corresponding to the 
–CH2– protons of PEI (2.8–3.1 ppm) and PEG (3.3–3.6 
ppm). Different degrees of PEG substitution on PEI-PEG 
and PEI-PEG-APRPG polymers were prepared, and a 0.5% 
PEG substitution was used in the following studies.
Preparation and characteristics  
of polyelectrolyte complex
The siRNA was mixed with PEI, PEI-PEG, and PEI-PEG-
APRPG in phosphate-buffered saline (pH 7.4) at the designed 
nitrogen to phosphate (N/P) ratio. The siRNA complexes 
(siRNA/PEI, siRNA/PEI-PEG, and siRNA/PEI-PEG-
APRPG) were spontaneously achieved via electrostatic 
interaction between cationic PEI and negative siRNA. 
The mixtures were then incubated for 30 minutes at room 
temperature.
Similarly, the DFA complexes (DFA/PEI, DFA/PEI-PEG, 
DFA/PEI-PEG-APRPG) were obtained by mixing DFA 
with PEI, PEI-PEG, and PEI-PEG-APRPG at a nitrogen to 
hydroxyl ratio of 4:1 in phosphate-buffered saline.
The hydrodynamic diameter and zeta potentials of freshly 
prepared complexes were measured using a Zetasizer Nano 
ZS ZEN3600 (Malvern, Worcestershire, UK) at 25°C. 
Measurements were performed in phosphate-buffered saline 
(pH 7.4). The shapes of the siRNA/PEI-PEG complexes 
and naked siRNA were evaluated by transmission electron 
microscopy.
gel retardation assay
The stability of naked siRNA and siRNA complexes against 
RNase A digestion was investigated. Aliquots of 15 µL com-
plexes corresponding to 1.33 µg of siRNA were incubated 
in 40 µg/mL RNase A at 37°C. Afterwards, an aliquot was 
removed from the sample at an indicated time interval and 
an equal volume of 1% sodium dodecyl sulfate was added 
to the sample, then manipulated at 65°C for 5 minutes, and 
the resulting mixtures were applied to 3% agarose gel, with 
electrophoresis carried out at 15 mA for 1 hour. The resulting 
gel was imaged on a Biometra transilluminator.
Transfection assay and cell proliferation 
inhibition assay in vitro
Human breast cancer cell line MCF-7 cells were provided by 
the Institute of Basic Medical Sciences Chinese Academy of 
Medical Sciences (Beijing, China) and grown and maintained 
in Dulbecco’s Modified Eagle’s Medium supplemented with 
10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/
mL streptomycin, and maintained at 37°C in a 5% carbon 
dioxide incubator.
MCF-7 cells were seeded at a density of 2 × 105 cells/
well in six-well cell plates and incubated at 37°C in a 5% 
carbon dioxide incubator. After 24 hours of incubation, cells 
achieved 80% confluency, and the media were replaced 
with Dulbecco’s Modified Eagle’s Medium containing the 
FITC-siRNA complexes. After 6 hours of incubation, the 
cells treated with FITC-siRNA complexes were lysed. FITC-
siRNA was quantified using a FACS Caliber flow cytometer 
from Becton Dickinson (New York, NY) with a 488 nm 
excitation laser and a 525 nm emission filter.
MCF-7 cells were seeded in 96-well plates at a density 
of 8000 cells/well and incubated at 37°C in a 5% carbon 
dioxide incubator. After 24 hours of incubation, the media 
were replaced with Dulbecco’s Modified Eagle’s Medium 
containing the siRNA complexes (40 nM of siRNA/well) 
and the corresponding polymers, respectively. Following 
5 hours of incubation at 37°C, the transfection media were 
then removed and replaced with fresh growth medium. After International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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72 hours of incubation, the media were replaced by 180 µL 
of fresh Dulbecco’s Modified Eagle’s Medium (10% fetal 
bovine serum) and 20 µL of 5 mg/mL MTT solution and 
incubated further for 4 hours away from light. The media 
were removed and 100 µL of dimethyl sulfoxide was added 
to the wells, and the absorbance was measured at 490 nm 
using a microplate reader. The proliferation-inhibiting ability 
of siRNA in the different complexes was evaluated by the 
difference in inhibition rate between siRNA complexes and 
the corresponding polymers.
Tissue distribution in tumor-bearing mice
Balb/C nude mice (5 weeks of age) were obtained from 
the Department of Laboratory Animal Science, Peking 
University Health Science Center (Beijing, China) and were 
housed under standard conditions with free access to food and 
water. All of the animal experiments adhered to the principles 
of care and use of laboratory animals, and were approved by 
the Institutional Animal Care and Use Committee of Peking 
University. The tumor model was generated by subcutaneous 
injection of MCF-7 cell suspension (2 × 106 cells) into the 
flank region of the mouse.
When the volume of the tumor reached 50 mm3, DFA 
complexes were administered through the tail vein at a dose 
of 10 µg/mouse and DFA alone was used as a control. After 
half an hour, the mice were sacrificed and the various tissues, 
including heart, liver, spleen, lung, kidney, and tumor, were 
harvested, washed with phosphate-buffered saline, and 
weighed. The tissues were homogenized in phosphate-buffered 
saline using an electric homogenizer. The tissue homogenates 
were centrifuged for 20 minutes at 4000 rpm (4°C). The DFA 
fluorescent intensity of the tissue supernatants was detected 
by a fluorospectrophotometer (RF-5301PC, Shimadzu, Kyoto, 
Japan) at 488 nm and 525 nm of excitation and emission 
wavelength, respectively. The amount of DFA in each tissue 
was calculated by relating fluorescent intensity to the standard 
curve and expressed as the mean ± standard deviation of the 
percentage of injected dose per gram of tissue.
VegF sirNA treatment in tumor-bearing 
mice
Balb/C nude mice (female, 4 weeks of age) were used 
in siRNA treatment. The tumor model was generated by 
subcutaneous injection of MCF-7 cell suspension (2 × 106 
cells) into a flank region of the mouse to establish the tumor 
model. When the volume of the tumor reached 250 mm3, the 
siRNA complexes containing 2 nmol siRNA were injected 
intravenously through the tail vein on days 1, 4, 8, and 12.
Tumor growth was monitored by a caliper to measure 
the major and minor axis. The respective tumor volume 
was determined based on the following formula: tumor 
volume = (major axis) × (minor axis)2/2. The relative tumor 
volume was used to compare the tumor growth tendency 
in each group based on the following formula: relative 
tumor volume = daily tumor volume/tumor volume on first 
injection day.
To determine the amount of VEGF in each solid tumor 
region, tumors were harvested from the tumor-bearing mice 
on days 8 and 22 after the initial injection. The tumors were 
weighed and homogenized in phosphate-buffered saline 
using a glass-teflon homogenizer. The tissue homogenates 
were centrifuged for 30 minutes at 13,500 rpm (4°C) to 
remove insoluble tissue debris and the supernatant was used 
for further analysis. The amount of protein was determined 
using a Bradford kit (Beyotime Institute of Biotechnology, 
Jiangsu, China). The amount of human VEGF produced 
in the tumor was determined using a human VEGF 
enzyme-linked immunosorbent assay kit (Boster Biological 
Technology, Wuhan, China) according to the manufacturer’s 
recommendation. The quantity of intratumoral VEGF protein 
(ng/mg protein) was equal to the amount of VEGF protein/
the amount of protein.
To determine the intratumoral level of VEGF mRNA, 
total RNA was isolated from about 80 mg of tumor tissue 
using TRIzol® Reagent and following the manufacturer’s 
recommendation. The concentration of RNA was detected 
by ultraviolet spectrophotometer (TU-1901, Purkinje, China) 
at 260 nm, and the A260/A280 ratio of 1.9–2.1 was reached 
when RNA was dissolved in tris-ethylenediamine tetra-acetic 
acid buffer (pH 8.0).
Reverse transcription polymerase chain reaction was 
performed using a RevertAidTM First Strand cDNA synthesis 
kit (MBI Fermentas, Burlington, ON) and SYBR® Premix 
Ex TaqTM II (TaKaRa, Otsu, Japan). cDNA synthesis was 
completed according to the manufacturer’s recommendation 
and polymerase chain reaction was carried out using an ABI 
Prism 7500 real-time polymerase chain reaction system 
under the following thermal cycling conditions: denaturation; 
one cycle 95°C for 30 seconds, polymerase chain reaction; 
40 cycles at 95°C for 5 seconds and at 60°C for 34 seconds. 
The polymerase chain reaction primers to detect human VEGF 
(forward: 5′-AGGAGGGCAGAATCATCACG-3′; reverse: 
5′-CAAGGCCCACAGGGATTTTCT-3′) and human β-actin 
(forward: 5′-TGTACGCCTCTGGCCGTACC-3′; reverse: 
5′-CCACGTCACACTTCATGATGG-3′) were custom 
synthesized by AuGCT Biotechnology (Beijing, China).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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On day 22 after initial injection of the siRNA complexes 
and phosphate-buffered saline, the tumor-bearing mice were 
euthanized by cervical dislocation and the tumors were 
harvested for immunohistochemical staining. The vessels 
were marked with rabbit antimouse CD34 antibody and 
rabbit streptavidin-peroxidase kit (Zhongshan Goldenbridge 
Biotechnology, Beijing, China). The colorimetric detection 
of microvessels was performed using a DAB detection kit 
(Zhongshan Goldenbridge Biotechnology) following the 
manufacturer’s recommendation. To determine intratumoral 
microvessel density, five independent areas (each microscope 
field is 0.100 mm2) were randomly selected in the hot areas, 
and images were obtained at a magnification of 200× under a 
microscope equipped with a Leica Q550CW imaging system 
(Somme, Germany). The microvessel density (t = number 
of vessels/mm2) was equal to the number of vessels in a 
microscope field/area of a microscope field.
statistical analysis
All data are given as the mean ± standard deviations or 
the mean ± standard errors of the mean of independent 
measurements. Statistical analysis was performed using 
SPSS software (v 13.0; SPSS Inc, Chicago, IL). Statistical 
significance was assigned for P values , 0.05.
Results
synthesis and characterization of PeI-Peg 
and PeI-Peg-APrPg derivatives
In Figure 1A, peaks at 2886 cm-1 and 1104 cm-1 were 
  attributed to the C–H stretching vibration of methylene 
and C–O stretching vibration of the ether linkage, which 
demonstrated the existence of –CH2–CH2–O in methyl 
PEG. In Figure 1B, in addition to the peaks of C–H and 
C–O stretching vibration of PEG, a new peak due to imide 
appeared at 1741 cm-1, demonstrating the existence of NHS 
and the structure of PEG-NHS. In Figure 1C, the peaks at 
2941 cm-1 and 3200∼3400 cm-1 (broad) were attributed to the 
C-H stretching vibration of methylene and N–H stretching 
vibration, which confirmed the –CH2–CH2–NH2 functional 
group of PEI. In Figure 1D, except for the peaks from N–H 
(3200–3400 cm-1), C–H (2886 cm-1), and C–O (1104 cm-1) 
stretching vibration, the peak at 1741 cm-1 disappeared, 
which indicated disappearance of NHS and the existence of 
–CH2–CH2–NH2 and –CH2–CH2–O functional groups. Thin-
layer chromatography (TLC) also revealed that the production 
of PEG-PEI was completed.
In the 1H-NMR of PEI-PEG (Figure 2A), the signals at δ 
2.5–2.8 (m) were attributed to the methylene group in PEI, 
the signal at δ 3.202 (s) was attributed to the H of CH3–O and 
δ 3.5 (m) was attributed to the methylene group in PEG. The 
integration ratio of PEI (δ 2.5–2.8) and PEG (δ 3.5) indicated 
that 8.68 molar PEG had been connected to one molar PEI and 
the molecular weight of PEI-PEG was calculated as 66,000.
A heterobifunctional PEG, ie, NHS-PEG-VS, was used as 
a linker between PEI and APRPG. In the first reaction step, 
the NHS group of heterobifunctional PEG was reacted with 
the amino terminal primary amine of a peptide that was pre-
activated by an excess of triethylamine in anhydrous dimethyl 
formamide. In the second reaction step, APRPG-PEG-VS were 
mixed with PEI in pH 9.4. MALDI-TOF-MS of VS-PEG-NHS 
and APRPG-PEG-NHS produced a broad peak centered at 
7589 m/z and 7980 m/z, and each peak was spaced by 44 Da, 
ie, the molecular weight of ethylene oxide monomer (Figure 3). 
The molecular weight increment of APRPG-PEG-NHS from 
VS-PEG-NHS was about 400 Da, which was in conformity 
with the molecular weight of APRPG peptide. This result 
confirmed the formation of APRPG-PEG-NHS.
The 1H-NMR of PEI-PEG-APRPG (Figure 2B) showed 
complete disappearance of the vinyl group (δ 6.2–6.4), the 
signals at δ 2.5–2.9 (m) were attributed to the methylene 
group in PEI, and the signal at δ 3.5 (m) was attributed to 
the methylene group in PEG. In the 1H-NMR of PEI-PEG-
APRPG, APRPG peptide signals could not be identified eas-
ily because signals from PEI-PEG overwhelmed the APRPG 
peptide signals. The conjugation degree of APRPG-PEG to 
PEI was calculated from the integral ratio of –CH2– protons 
of PEI (δ 2.5–2.9) to PEG (δ 3.5). Based on this estimate, 
an average of about 15.86 APRPG-PEG molecules attached 
to each 25 kDa PEI molecule, and the molecular weight of 
PEI-PEG-APRPG was calculated as 150,024.38 Da.
characteristics of sirNA complexes
The size and zeta potential of the siRNA complexes were 
about 20–50 nm and about 17.2 mV measured by Zetasizer, 
respectively. The particle diameter of siRNA/PEI-PEG com-
plexes by transmission electron microscopy was 30–40 nm, 
and they had a regular spheroid appearance (Figure 4).
To identify the formation of siRNA/PEI-PEG complexes, 
agarose gel electrophoresis was performed at different 
N/P ratios, and the gel was immersed in ethidium bromide 
  solution for 20 minutes before imaging (Figure 5). The 
movement of siRNA in the gel became slower as the amount 
of PEI-PEG increased, demonstrating that PEI-PEG bound 
to siRNA by   neutralizing its charge. At N/P ratios exceed-
ing the neutralization composition, the complex micelles 
migrated slightly toward the anode, suggesting that they had International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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a small positive charge. Complete complex formations were 
achieved at an N/P ratio of approximately 10, suggesting 
that all negatively charged siRNA phosphate residues were 
saturated with PEI-PEG.
stability of sirNA/PeI-Peg complexes  
in rNase A
To investigate the stability of siRNA/PEI-PEG complexes in 
the presence of RNase A, naked siRNA and siRNA/PEI-PEG 
complexes were incubated in 40 µg/mL RNase A at 37°C. The 
naked siRNA showed degradation after 24 hours of incubation 
in the RNase A-containing medium (Figure 6A). In contrast, 
siRNA/PEI-PEG complexes could last for up to 36 hours 
without a significant loss of integrity under these conditions 
(Figure 6B). This result suggested that PEI-PEG could increase 
the stability of siRNA, which was likely due to the presence of 
a shell layer that sterically hinders access of nucleases to the 
siRNA which is set into the branch structure of PEI.
3500 3000 2500 2000 1500 1000 500
Wavenumbers (cm−1)
A
B
C
D
Figure 1 Fourier transform infrared spectra of polymers. (A) Methoxypolyethylene glycol, (B) N-hydroxysuccinimide-polyethylene glycol, (C) polyethylenimine, and   
(D) polyethylenimine-polyethylene glycol.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Transfection and cell proliferation 
inhibition assay in McF-7 cells in vitro
We compared the effect of different factors on the transfection 
efficiency of the siRNA complexes. When using Dulbecco’s 
Modified Eagle’s Medium without serum as the transfection 
mediator of MCF-7 cells, the transfection efficiency of 
the siRNA/PEI complexes was low, but the transfection 
  efficiency of the siRNA/PEI-PEG and siRNA/PEI-PEG-
APRPG complexes was relatively high (Figure 7A).
In the cell proliferation inhibition assay, we investigated 
the inhibitory effect of the polymers using a series of different 
concentrations. The results showed that polymers in the range 
of experimental concentrations had no cytotoxicity (data not 
shown). Based on this, we detected the inhibitory interaction 
between siRNA complexes and the corresponding polymers, 
and evaluated the proliferation-inhibiting ability of siRNA in 
the different complexes by the difference in inhibition rate. 
The inhibiting proliferation ability of siRNA complexes 
was as follows: siRNA/PEI-PEG-APRPG . siRNA/PEI-
PEG . siRNA/PEI, and there was a significant difference 
between the siRNA/PEI and siRNA/PEI-PEG-APRPG com-
plexes (P , 0.05, Figure 7B) at an N/P of 100 and a siRNA 
concentration of 40 nM.
Tissue distribution in tumor-bearing mice
DFA and siRNA both have anionic groups which can 
associate with cationic groups of PEI through electrostatic 
interaction. To design an effective formulation for nucleic 
acids and   peptides containing multiple-charged groups, 
DFA was used as a model multiple-charged compound 
and   combined with cationic lipids, and these complexes 
were wrapped with neutral lipids.18 Our investigations of 
the tissue distribution of PEI derivatives were conducted 
using DFA as a model multiply-charged compound because 
of its satisfactory stability and adequate fluorescence. 
Figure 8 shows the tissue distribution of DFA in MCF-7 
tumor-bearing mice.   Compared with DFA, the amount of 
DFA complexes (DFA/PEI, DFA/PEI-PEG, and DFA/PEI-
PEG-APRPG) were a little smaller in the heart and lung, but 
higher in the spleen, liver, kidney, and tumor tissue. In the 
liver, there was a significant difference (P , 0.01) between 
the uptake of DFA alone and the DFA complexes (DFA/
PEI-PEG-APRPG, DFA/PEI-PEG, and DFA/PEI). The 
major pathway for the removal of these nanoscale complexes 
from the blood appeared to be capture in the mononuclear 
phagocyte system, especially in the liver.19 DFA could be 
rapidly eliminated in the kidney,20 and the higher amount of 
DFA complexes (DFA/PEI, DFA/PEI-PEG, and DFA/PEI-
PEG-APRPG) in the kidney suggests that the PEI derivatives 
can prevent the drug from being eliminated in some extent. 
However, the amount of drug in some of the normal organs 
was more than that in the tumor cells. The significantly 
(P , 0.05) higher amount of DFA/PEI-PEG-APRPG than 
DFA, DFA/PEI and DFA/PEI-PEG in the tumor cells 
suggests that, when modified with APRPG peptide, these 
complexes could enhance target accumulation in the tumor. 
APRPG only adheres to neovascular endothelial cells, which 
limits access to normal cells.
VegF sirNA treatment in tumor-bearing 
mice
To investigate the effect of siRNA treatment, the tumor 
size was investigated every 3 days after the initial injection. 
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Relative tumor volume was used to detect the different 
effects (Figure 9A). The results showed that the tumor treated 
with phosphate-buffered saline had the most rapid growth 
rate. The siRNA complexes (siRNA/PEI and siRNA/PEI-
PEG-APRPG) had a stronger tumor inhibition effect than 
the siRNA. The tumor volumes were significantly different 
for siRNA/PEI-PEG-APRPG complexes (P , 0.01) and 
siRNA/PEI complexes (P , 0.05) compared with phosphate-
buffered saline on day 7 after two injections. Afterwards, 
the siRNA group had a significant difference compared with 
phosphate-buffered saline (P , 0.05), occurring on day 10 
after three siRNA injections. The siRNA/PEI-PEG-APRPG 
complexes showed highest inhibition of tumor growth.
Immunohistochemical staining of tumor-associated 
microvessels showed a relationship between suppression 
of VEGF expression and intratumoral neovascularization. 
The higher the microvessel density, the worse the inhibit-
ing effect. On day 22 after the initial injection, the tumors 
were harvested for immunohistochemical staining to observe 
neovascularization. The microvessel density quantified by 
number of microvessels per unit area showed the effects of 
the different formulations (Figure 9B). The mean value of 
microvessel density for siRNA/PEI-PEG-APRPG, siRNA/
PEI, and siRNA showed a significant decline compared with 
A
50 nm 100 nm
B
Figure 4 Transmission electron microscope images for (A) small interfering rNA/
polyethylenimine-polyethylene  glycol  complexes  and  (B)  naked  small  interfering 
rNA solution in phosphate-buffered saline (7.4).
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that in the phosphate-buffered saline group (P , 0.05). The 
results suggest that VEGF siRNAs had an inhibitory effect 
on microvessel formation. Specimens treated with siRNA/
PEI-PEG-APRPG complexes showed the greatest inhibitory 
effect in mean value of microvessel density.
The level of VEGF could express the gene silence effect 
of VEGF siRNA. There was significant inhibition for siRNA/
PEI-PEG-APRPG complexes, siRNA/PEI complexes, and 
siRNA on day 22 after the initial injection, and the siRNA/
PEI-PEG-APRPG complexes had the most inhibiting effect 
on the expression of VEGF protein (Figure 9C).
The VEGF mRNA in tumors was detected by the 
reverse transcription polymerase chain reaction. The data 
were analyzed by the 2-∆∆Ct method. The higher the value, 
the more the VEGF mRNA. The siRNA/PEI-PEG-APRPG 
complexes showed the lowest level of VEGF mRNA on 
days 8 and 22 after injection (Figure 9D), and there was a 
significant difference between the siRNA/PEI-PEG-APRPG 
complexes and siRNA alone. This suggests that the PEI-
PEG-APRPG carrier could deliver siRNA efficiently to the 
tumor in which siRNA expresses a gene silence effect and 
reduces the level of mRNA. Comparing the results from day 
8 and day 22, we found that on day 8 (two injections, 4 days 
after the last injection) the mRNA level was significantly 
different (P , 0.05) between siRNA/PEI-PEG-APRPG and 
siRNA, but on day 22 (four injections, 10 days after the last 
injection) there was no significant difference. The silencing 
effect is decreased with the passage of time. This indicates 
the importance of multiple injections of siRNA.
Discussion
Suppression of VEGF gene expression is an important factor in 
tumor growth and regulates tumor angiogenesis, representing 
a novel approach to cancer treatment. The MCF-7 cell line is a 
type of human breast carcinoma overexpressing VEGF, leading 
to increased tumor angiogenesis. siRNA has become a major 
strategy in gene therapy. VEGF siRNA can degrade homologic 
mRNA by forming an RNA-induced silencing complex with 
other cellular proteins.21 There are some challenges using 
siRNA therapy, ie, “off-target” effects, immune stimulation, 
and delivery issues,22 the latter being the most important. Naked 
siRNA has poor intracellular uptake, limited blood stability, 
0 .25 .5 124681 22 42 8
A B
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Figure 6 stability of (A) naked small interfering rNA and (B) small interfering rNA/polyethylenimine-polyethylene glycol complexes against rNase A digestion.
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Figure  5  Agarose  electrophoresis  of  small  interfering  rNA/polyethylenimine-
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and nonspecific immune stimulation. To solve these problems, 
modified siRNA, cationic carriers and ligand-targeting have 
been used in this type of vector delivery.
Cationic polymers assemble simply with negatively 
charged siRNA by electrostatic interactions and protect 
siRNA from RNase degradation. PEI has high transfection 
efficiency which is attributable to the large number of NH2 
on the surface and “proton sponge effect”, which enables 
it to escape from the low pH of the endosome and release 
siRNA into the cytoplasm. The positive net charge of the 
complexes inhibits their aggregation due to electrostatic 
repulsion and improves their interaction with negatively 
charged extracellular matrix components and thus their 
  cellular uptake.23
Proper modification, such as PEGylation, can decrease 
the toxicity24 and increase the transfection efficiency of PEI 
in vitro.25 PEG has unique qualities, including high solubility, 
and lack of toxicity and immunogenicity. PEGylation is used 
to improve stability, solubility, and bioavailability.26 Cancer 
therapy requires high efficiency and specificity. Active 
  targeting via antibodies and peptides achieves more selective 
drug delivery to tumor tissues. APRPG peptide used as an 
angiogenic vessel-homing peptide could selectively target 
tumor neovasculature.12,27 In our study, PEI-PEG-APRPG 
was developed by incorporating APRPG peptide into PEI 
via a NHS-PEG-VS spacer.
PEI-PEG and PEI-PEG-APRPG combined with siRNA 
showed higher transfection efficiency than PEI (Figure 7A), 
and improved the cell proliferation-inhibiting effect of siRNA 
compared with PEI (Figure 7B). DFA/PEI-PEG showed more 
accumulation than DFA/PEI in all the tissues except for the 
liver and kidney (Figure 8) in vivo. This suggests that PEGy-
lation can enhance the retention time of the drug and target the 
tumor by the enhanced permeability and retention effect. The 
higher transfection efficiency and stronger cell proliferation-
inhibiting effect of siRNA/PEI-PEG-APRPG complexes 
in vitro, and more accumulation of DFA/PEI-PEG-APRPG 
complexes in tumor in vivo compared with that of siRNA/
PEI-PEG and DFA/PEI-PEG complexes demonstrates the 
targeting efficacy of the vessel-homing APRPG peptide. 
Meanwhile, siRNA/PEI-PEG-APRPG complexes reduce the 
tumor growth rate, density of microvessels, VEGF produc-
tion, and VEGF mRNA in vivo, demonstrating that, when 
comodified with PEGylation and APRPG, PEI can enhance 
the gene silence effect. In summary, PEI-PEG-APRPG is a 
promising strategy for delivery of siRNA to tumor tissues 
by enhanced passive targeting with the enhanced retention 
and permeation effect (via PEGylation), as well as active 
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targeting to the tumor angiogenic vasculature (via conjuga-
tion of the targeting moiety APRPG peptide).
Our results are similar to those previously reported by 
other investigators. APRPG-PEG-Lip-SU1498 was shown 
to inhibit VEGF-stimulated endothelial cell proliferation in 
vitro, significantly decrease tumor microvessel density in 
colon 26 NL-17 cell-bearing mice, and prolong the survival 
time of these mice.13 In addition to APRPG peptide, other 
active targeting methods have also shown a good effect for 
the delivery of drugs. RGD peptide which targets integrin 
expression and is upregulated at neovasculature sites has been 
reported to be a nanoparticle ligand which can selectively 
deliver siRNA to tumor tissue.28 Murase et al reported that 
dual-targeting liposomes modified with APRPG peptide 
and Gly-Asn-Gly-Arg-Gly peptides containing doxorubicin 
strongly suppressed tumor growth in colon 26 NL-17 
carcinoma-bearing mice.29
Naked siRNA is rapidly eliminated by liver and kidney 
after intravenous administration, and chemically modified 
siRNA has been proposed to improve nuclease resistance 
and uptake by target cells. Other researchers have also 
identified that replacement of the phosphodiester group 
with a phosphothioate group at the 3′-end and modification 
with an O-methyl group (2′-O-Me) or a fluoro (2′-F) group 
resulted in a prolonged half-life and RNA inhibitor   activity 
in cultured cells.30,31 Furthermore, chemically modified 
siRNA could reduce “off-target” transcript silencing.32 
2′-O-modified RNAs could improve their stability against 
hydrolysis by nucleases, extend the duration of effects, 
eliminate dsRNA-induced inflammatory responses, and 
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enhance their hybridization affinity for the target RNAs.33–35 
They enhance the half-life of siRNA in serum, suggesting 
that these modifications can enhance the pharmacokinetic 
properties, knockdown activity of siRNAs, and be suitable 
for potential therapeutic application of synthetic siRNAs in 
vivo.36,37 We used 2′-O-Me-modified siRNA in vivo. Our 
results show that this kind of siRNA has an efficient silenc-
ing effect, inhibits tumor growth, reduces the number of 
microvessels, and suppresses the expression of VEGF protein 
(Figures 9A–C).
Tumor inhibition and gene silencing were observed in 
mice treated with two or four intravenous injections contain-
ing 54 µg or 108 µg of siRNA formulated in PEI. This dose 
corresponds to approximately 3 mg/kg, which is relatively 
low compared with the doses used in other studies demon-
strating siRNA efficacy in vivo.33,38–40 Nevertheless, the PEI 
formulation was also shown to facilitate delivery of siRNA 
to tumor tissue.
The expression of mRNA injected with siRNA/PEI 
complexes was lower than for siRNA (Figure 9D) as 
opposed to the level of VEGF protein shown in Figure 9C. 
The reason may be the tumor mRNA elimination rate was 
not synchronized with the expression of VEGF protein. In 
addition, siRNA is known to have an immunostimulatory 
effect on interferon alpha, which can downregulate the 
expression of VEGF and exhibits antitumor activity by an 
antiangiogenesis mechanism.41 This may be one reason for 
the difference between the levels of VEGF and mRNA.
siRNA cannot completely inhibit the expression of 
VEGF in MCF-7 cells, and the formation of tumor vessels is 
regulated by many cell factors. Single VEGF inhibition could 
not completely suppress angiogenesis and tumor growth. 
Furthermore, the effect of siRNA is temporary. Different 
effects of siRNAs or other drugs should be combined in 
cancer therapy using multiple tumor inhibition pathways.
Conclusion
We investigated a tumor-targeted system whereby PEI-PEG-
APRPG was used to deliver siRNA in vitro and in vivo. 
Treatment with VEGF siRNA complexes had an inhibitory 
effect on cell proliferation and tumor growth. The complexes 
suppressed the increasing volume of the tumors, inhibited 
the formation of microvessels, and reduced the expression 
of VEGF protein and mRNA. The siRNA/PEI-PEG-APRPG 
complexes provided more efficient antiangiogenic therapy 
than siRNA/PEI and siRNA. This research shows that 
APRPG peptide as a target substance with PEG-PEI may 
improve siRNA delivery. It also supports gene therapy as a 
method to overcome the difficulty of siRNA delivery to the 
target site. The PEI-PEG-APRPG complex may be a useful 
nonviral gene vector for cancer therapy.
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